Detection of autoantibody to aldolase B in sera from patients with troglitazone-induced liver dysfunction

Toxicology

Volumn 216, Issue 1, 2005, Pages 15-23

  Maniratanachote, Rawiwan ^a   Shibata, Ayaka ^a   Kaneko, Shuichi ^a   Yamamori, Ikuo ^b   Wakasugi, Takanobu ^c   Sawazaki, Takeshi ^d   Katoh, Kanefusa ^e   Tokudome, Shogo ^f   Nakajima, Miki ^a   Yokoi, Tsuyoshi ^a  

^a KANAZAWA UNIVERSITY   (Japan)

^b JAPANESE RED CROSS NAGOYA FIRST HOSPITAL   (Japan)

^c Fukui Prefectural Hospital   (Japan)

^d Showa Denko Materials Co   (Japan)

^e INSTITUTE FOR DEVELOPMENTAL RESEARCH   (Japan)

^f DOKKYO MEDICAL UNIVERSITY   (Japan)

Author keywords

Aldolase B; Autoantibody; Liver dysfunction; Thiazolidinediones; Troglitazone

Indexed keywords

ALANINE AMINOTRANSFERASE; ALDOLASE B; ANTIDIABETIC AGENT; AUTOANTIBODY; AUTOANTIGEN; FRUCTOSE BISPHOSPHATE ALDOLASE; TROGLITAZONE; UNCLASSIFIED DRUG;

ADULT; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; AMINO ACID ANALYSIS; ANTIBODY DETECTION; ANTIBODY PRODUCTION; ANTIBODY TITER; ANTIGEN ANTIBODY REACTION; ARTICLE; BLOOD CHEMISTRY; BLOOD EXAMINATION; CASE REPORT; CHRONIC HEPATITIS; CONTROLLED STUDY; DISEASE EXACERBATION; DISEASE SEVERITY; DRUG WITHDRAWAL; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOREACTIVITY; LIVER CIRRHOSIS; LIVER DYSFUNCTION; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL; TWO DIMENSIONAL GEL ELECTROPHORESIS;

AGED; ALANINE TRANSAMINASE; AUTOANTIBODIES; CHROMANS; DIABETES MELLITUS, TYPE 2; ELECTROPHORESIS, GEL, TWO-DIMENSIONAL; ELECTROPHORESIS, POLYACRYLAMIDE GEL; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; FRUCTOSE-BISPHOSPHATE ALDOLASE; HEPATITIS, TOXIC; HUMANS; HYPOGLYCEMIC AGENTS; IMMUNOBLOTTING; LIVER; LIVER CIRRHOSIS; LIVER DISEASES; MALE; MIDDLE AGED; SUBCELLULAR FRACTIONS; THIAZOLIDINEDIONES;

EID: 27444439653     PISSN: 0300483X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.tox.2005.07.012     Document Type: Article

References (38)

1. K.P. Batts, and J. Ludwig Chronic hepatitis. An update on terminology and reporting Am. J. Surg. Pathol. 19 1995 1409 1417
2. M. Bourdi, W. Chen, R.M. Peter, J.L. Martin, J.T. Buters, S.D. Nelson, and L.R. Pohl Human cytochrome P450 2E1 is a major autoantigen associated with halothane hepatitis Chem. Res. Toxicol. 9 1996 1159 1166
3. M. Bourdi, D. Larrey, J. Nataf, J. Bernuau, D. Pessayre, M. Iwasaki, F.P. Guengerich, and P.H. Beaune Anti-liver endoplasmic reticulum autoantibodies are directed against human cytochrome P-450IA2. A specific marker of dihydralazine-induced hepatitis J. Clin. Invest. 85 1990 1967 1973
4. C. Brown, B.H. Toh, J.S. Pedersen, F.M. Clarke, I.R. Mackay, and I. Gust Autoantibody to aldolase in acute and chronic hepatitis Pathology 19 1987 347 350
5. T.P. Ciaraldi, A. Gilmore, J.M. Olefsky, M. Goldberg, and K.A. Heidenreich In vitro studies on the action of CS-045, a new antidiabetic agent Metabolism 39 1990 1056 1062
6. J. Descotes Autoimmunity and toxicity testing Toxicol. Lett. 112-113 2000 461 465
7. T. Fujiwara, A. Okuno, T. Yoshioka, and H. Horikoshi Suppression of hepatic gluconeogenesis in long-term troglitazone treated diabetic KK and C57BL/KsJ-db/db mice Metabolism 44 1995 486 490
8. T. Fujiwara, S. Yoshioka, T. Yoshioka, I. Ushiyama, and H. Horikoshi Characterization of new oral antidiabetic agent CS-045: Studies in KK and ob/ob mice and Zucker fatty rats Diabetes 37 1988 1549 1558
9. N. Gitlin, N.L. Julie, C.L. Spurr, K.N. Lim, and H.M. Juarbe Two cases of severe clinical and histologic hepatotoxicity associated with troglitazone Ann. Intern. Med. 129 1998 36 38
10. J. Gut, U. Christen, and J. Huwyler Mechanisms of halothane toxicity: novel insights Pharmacol. Ther. 58 1993 133 155
11. H. Haimoto, N. Kurobe, S. Hosoda, and K. Kato Sensitive enzyme immunoassay for human aldolase B Clin. Chim. Acta 181 1989 27 36
12. J.C. Homberg, C. Andre, and N. Abuaf A new anti-liver-kidney microsome antibody (andi-LKM2) in tienilic acid-induced hepatitis Clin. Exp. Immunol. 55 1984 561 570
13. G.P. Jevon Grade and stage in chronic hepatitis Pediatr. Dev. Pathol. 4 2001 372 380
14. C. Ju, and J.P. Uetrecht Mechanism of idiosyncratic drug reaction: relative metabolites formation, protein binding and the regulation of the immune system Curr. Drug Metab. 3 2002 367 377
15. J.G. Kenna, T.L. Knight, and F.N.A.M. van Pelt Immunity to halothane metabolite-modified proteins in halothane hepatitis Ann. N. Y. Acad. Sci. 685 1993 646 661
16. ®) Rinsho-Iyaku 14 1998 461 466
17. A. Lanzavecchia How can cryptic epitopes trigger autoimmunity? J. Exp. Med. 181 1995 1945 1948
18. J.S. Leeder, R.J. Riley, V.A. Cook, and S.P. Spielberg Human anti-cytochrome P450 antibodies in aromatic anticonvulsant-induced hypersensitivity reactions J. Pharmacol. Exp. Ther. 263 1992 360 367
19. O.H. Lowry, N.J. Rosebrough, A.L. Farr, and R.J. Randall Protein measurement with the Folin phenol reagent J. Biol. Chem. 193 1951 265 275
20. M.P. Manns, and P. Obermayer-Straub Cytochromes P450 and uridinetriphosphate-glucuronosyltransferases: model autoantigens to study drug-induced, virus-induced and autoimmune liver disease Hepatology 26 1997 1054 1066
21. B.A. Neuschwander-Tetri, W.L. Isley, J.C. Oki, S. Ramrakhiani, S.G. Quiason, N.J. Phillips, and E.M. Brunt Troglitazone-induced hepatic failure leading to liver transplantation Ann. Intern. Med. 129 1998 38 41
22. P.H. O'Farrell High resolution two-dimensional electrophoresis J. Biol. Chem. 250 1975 4007 4021
23. B.K. Park, M. Pirmohamed, and N.R. Kitteringham Role of drug disposition in drug hypersensitivity: a chemical, molecular and clinical perspective Chem. Res. Toxicol. 11 1998 969 988
24. E. Penhoet, T. Rajkumar, and W.J. Rutter Multiple forms of fructose diphosphate aldolase in mammalian tissues Proc. Natl. Acad. Sci. U.S.A. 56 1966 1275 1282
25. M. Pirmohamed, A.M. Breckenridge, N.R. Kitteringham, and B.K. Park Adverse drug reactions Br. Med. J. 316 1998 1295 1298
26. L.R. Pohl, H. Satoh, D.D. Christ, and J.G. Kenna The immunologic and metabolic basis of drug hypersensitivities Ann. Rev. Pharmacol. 28 1988 367 387
27. N.R. Pumford, B.M. Martin, D. Thomassen, J.A. Burris, J.G. Kenna, J.L. Martin, and L.R. Pohl Serum antibodies from halothane hepatitis patients react with the rat endoplasmic reticulum protein Erp72 Chem. Res. Toxicol. 6 1993 609 615
28. M.A. Robin, M. Maratrat, M. Le Roy, F.P. Le Breton, E. Bonierbale, P. Dansette, F. Ballet, D. Mansuy, and D. Pessayre Antigenic targets in tienilic acid hepatitis: Both cytochrome P450 2C11 and 2C11-tienilic acid adducts are transported to the plasma membrane of rat hepatocytes and recognized by human sera J. Clin. Invest. 98 1996 1471 1480
29. C. Rothwell, E.J. McGuire, D.M. Altrogge, H. Masuda, and F.A. de la Iglesia Chronic toxicity in monkeys with the thiazolidinedione antidiabetic agent troglitazone J. Toxicol. Sci. 27 2002 35 47
30. W.J. Rutter Evolution of aldolase Fed. Proc. 23 1964 1248 1257
31. W.J. Rutter, O.C. Richards, and B.M. Woodfin Comparative studies of liver and muscle aldolase. I. Effect of carboxypeptidase on catalytic activity J. Biol. Chem. 236 1961 3193 3197
32. F. Schapira, C. Gregori, and A. Hatzfeld Isoelectrofocusing of aldolase B from normal human livers and from livers with hereditary fructose intolerance Clin. Chim. Acta 78 1977 1 8
33. A. Shibuya, M. Watanabe, Y. Fujita, K. Saigenji, S. Kuwao, H. Takahashi, and H. Takeuchi An autopsy case of troglitazone-induced fulminant hepatitis Diabetes Care 21 1998 2140 2143
34. J.N. Tettey, J.L. Maggs, W.G. Rapeport, M. Pirmohamed, and B.K. Park Enzyme induction dependent bioactivation of troglitazone and troglitazone quinone in vivo Chem. Res. Toxicol. 14 2001 965 974
35. I. Watanabe, A. Tomita, M. Shimizu, M. Sugawara, H. Yasumo, R. Koishi, T. Takahashi, K. Miyoshi, K. Nakamura, T. Izumi, Y. Matsushita, H. Furukawa, H. Haruyama, and T. Koga A study to survey susceptible genetic factors responsible for troglitazone-associated hepatotoxicity in Japanese patients with type 2 diabetes mellitus Clin. Pharmacol. Ther. 73 2003 435 455
36. T. Watanabe, Y. Ohashi, M. Yasuda, M. Takaoka, T. Furukawa, T. Yamoto, A. Sanbuissho, and S. Manabe Was it possible to predict liver dysfunction caused by troglitazone during the nonclinical safety studies? Iyakuhin Kenkyu 30 1999 537 546
37. P.B. Watkins, and R.W. Whitcomb Hepatic dysfunction associated with troglitazone N. Engl. J. Med. 338 1998 916 917
38. H. Yamazaki, A. Shibata, M. Suzuki, M. Nakajima, N. Shimada, F.P. Guengerich, and T. Yokoi Oxidation of troglitazone to a quinone-type metabolite catalyzed by cytochrome P-450 2C8 and P-450 3A4 in human liver microsomes Drug Metab. Dispos. 27 1999 1260 1266